Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

Dr. Alexandre Zlotta delivered the State-of-the-art lecture Who really needs surgery after neo-adjuvant chemotherapy? Dr.

Bladder cancer is the ninth most common cancer worldwide, diagnosed in more than 614,000 people each year globally, including an estimated 85,000 people in the U.S. 2,3 MIBC represents approximately ...

Dr. Aleksander Słusarczyk presented the clinical case of a 75-year-old woman who presented with a two-month history of hematuria. Her medical history was notable for diabetes, prior myocardial ...

BERLIN -- Patients with cisplatin-ineligible bladder cancer had huge reductions in clinical events and cancer death when treated with a novel combination therapy before and after surgery, according to ...